Dear reader,
This issue of Human Vaccines & Immunotherapeutics starts with a Profile of the biotech company GeneOne Life Sciences (Maslow, p. 2548) and a Portrait of Dr. Marie-Paule Kieny of INSERM, Paris (Kieny, p. 2550).
We are delighted to present a Special Focus on Immunotherapy of Autoimmune Diseases with seven articles summarizing recent advances in the field. Specifically, literature reviews examine AI techniques in the treatment of Sjögren syndrome (Foulquier, p. 2553), immunotherapy of systemic sclerosis (Katsiari, p. 2559) and Guillain-Barré syndrome (Liu, p. 2568), the significance of gut microbiota for treatment of type 1 diabetes (Pearson, p. 2580), and immunotherapy of inflammatory bowel disease (Catalan-Serra, p. 2597); a research article present results from the CORPUS study on elderly patients with rheumatoid arthritis receiving anti-TNFα treatment (Oishi, p. 2612), and a review discusses humanized animal models of autoimmune diseases (Huang, p. 2618).
Eight articles on Licensed Vaccines include an immunogenicity and safety trial of a second-dose MMR vaccine in healthy ≥7 year-olds (Abu-Elyazeed, p. 2624), a systematic review of immunogenicity of inactivated and oral polio vaccines vs. inactivated vaccine alone (Tang, p. 2636), sero-profiling of poliovirus in Guangdong, China (Tan, p. 2644), a survey of knowledge, attitudes and uptake of pneumococcal, influenza and tetanus vaccines among Turkish hospital patients (Hamidi, p. 2649), evaluation of post-exposure rabies prophylaxis in Polish children (Krzowska-Firych, p. 2660), and a case study of rabies post-exposure prophylaxis for a male with severe Henoch Schönlein purpura following rabies vaccination (Zhu, p. 2666).
The Novel Vaccines section presents a review on the development of GBS vaccine (Song, p. 2669), and three research studies on safety and immunogenicity of a 4-valent Staphylococcus aureus vaccine in Japanese adults (Inoue, p. 2682), statistical methods for evaluating vaccine immunogenicity in complex clinical trial data (Yu, p. 2692), and one-year immunogenicity data for a plague subunit vaccine in Chinese adults (Hu, p. 2701).
Four Influenza-related articles include analysis of impact of EU policies on vaccination rates (Blank, p. 2706), a survey revealing low awareness and vaccine uptake among elderly Chinese from Shanghai (Ye, p. 2715), characterization of factors influencing vaccine coverage among adults in Quebec (Baron, p. 2722), and a commentary on passive immunization with hemagglutinin-specific MAbs (Rudraraju, p. 2728).
The Acceptance section features a review on ameliorating vaccine-induced pain and stress in children and adolescents (Lee, p. 2737) and a predictive behavioral model of parental intentions to vaccinate their children (Zhou, p. 2748).
Two articles on Rotavirus report on lower respiratory tract infections following vaccination with RV1 or RV5 in the US (Haber, p. 2755) and barriers to vaccination in India (Apte, p. 2760).
Finally we present a clinical trial of the 10-valent Pneumococcal conjugate vaccine children with chronic lung disease (O’Grady, p. 2768), analysis of Hepatitis A and B vaccination completion in US adults (Ghaswalla, p. 2780), novel adjuvant Technology based on iron oxide nanoparticles (Marques Neto, p. 2786), and a Letter (Polat, p. 2802) with a response (Dretler, p. 2803) on a fatal case of Meningococcal disease in a vaccinated child receiving eculizumab.
Our monthly News, Policy and Profiles (NP&P) track offers a selection of the latest news in the field of vaccines and immunotherapeutics. In this section we also regularly publish opinion pieces on timely, interesting and controversial topics related to vaccines and immunotherapeutics, profiles of companies and organizations, as well as portraits of distinguished scientists in our field. Please contact Acquisitions Editor Adam Weiss ([email protected]) with your ideas for commentaries, opinion pieces, profiles and portraits. Your suggestions for and contributions to our N&P&P track are always welcome!
Sincerely,